A method and system for preoperative thrombosis risk assessment for arteriovenous fistula surgery

Abstract

The application provides a kind of for arteriovenous fistula preoperative thrombosis risk assessment method and system, it is related to medical data processing field, the method comprises: based on the medical history information, treatment information and postoperative thrombosis monitoring information of multiple arteriovenous fistula surgical patients, determine multiple thrombosis risk related diseases, thrombosis risk related operation and thrombosis risk related drug, determine multiple arteriovenous fistula surgical patient type;Based on the medical history information and treatment information of the arteriovenous fistula surgical patient to be operated, determine the arteriovenous fistula surgical patient type to which the arteriovenous fistula surgical patient to be operated belongs, obtain the preoperative detection information of the arteriovenous fistula surgical patient to be operated, combine the key preoperative detection factor corresponding to the arteriovenous fistula surgical patient type to which the arteriovenous fistula surgical patient to be operated belongs and the influence weight corresponding to the key preoperative detection factor, carry out arteriovenous fistula preoperative thrombosis risk assessment, with the advantages of improving the efficiency and accuracy of arteriovenous fistula preoperative thrombosis risk assessment.

Description

TECHNICAL FIELD

[0001] The present application relates to the field of medical data processing, and particularly relates to a method and system for evaluating thrombosis risk before arteriovenous fistula surgery. BACKGROUND

[0002] Autologous arteriovenous fistula (AVF) is the most important dialysis access for maintenance hemodialysis (MHD) patients, which can ensure patients to obtain sufficient blood flow, and is the "lifeline" of maintenance hemodialysis patients, so the normal operation of its function determines the smooth completion of hemodialysis. Although autologous arteriovenous fistula has many advantages such as relatively longer service life and low maintenance cost, its service life is not permanent, and thrombosis and vascular access stenosis of the fistula are the primary and main causes of autologous arteriovenous fistula dysfunction.

[0003] In the prior art, in the absence of a unified evaluation tool, doctors mainly rely on personal experience and intuition to evaluate the thrombosis risk after arteriovenous fistula surgery. This evaluation method is often affected by the subjective judgment of doctors, which may lead to inaccurate or inconsistent risk evaluation.

[0004] Therefore, it is necessary to provide a method and system for evaluating thrombosis risk before arteriovenous fistula surgery, to improve the efficiency and accuracy of thrombosis risk evaluation before arteriovenous fistula surgery. SUMMARY

[0005] The application provides a method and system for evaluating thrombosis risk before arteriovenous fistula surgery, wherein the method comprises: obtaining medical information of a plurality of arteriovenous fistula surgery patients, wherein the medical information at least includes medical history information, treatment information, preoperative detection information and postoperative thrombosis monitoring information; determining a plurality of thrombosis risk related diseases, a plurality of thrombosis risk related operations and a plurality of thrombosis risk related drugs based on the medical history information, the treatment information and the postoperative thrombosis monitoring information of the plurality of arteriovenous fistula surgery patients; determining a plurality of arteriovenous fistula surgery patient types based on the medical information of the plurality of arteriovenous fistula surgery patients and the plurality of thrombosis risk related diseases, the plurality of thrombosis risk related operations and the plurality of thrombosis risk related drugs; for each arteriovenous fistula surgery patient type, determining a key preoperative detection factor corresponding to the arteriovenous fistula surgery patient type and an influence weight corresponding to the key preoperative detection factor based on the preoperative detection information and the postoperative thrombosis monitoring information of the plurality of arteriovenous fistula surgery patients included in the arteriovenous fistula surgery patient type; determining an arteriovenous fistula surgery patient type to which a to-be-arteriovenous fistula surgery patient belongs based on the medical history information and the treatment information of the to-be-arteriovenous fistula surgery patient; obtaining preoperative detection information of the to-be-arteriovenous fistula surgery patient based on the arteriovenous fistula surgery patient type to which the to-be-arteriovenous fistula surgery patient belongs; and performing thrombosis risk evaluation before arteriovenous fistula surgery based on the preoperative detection information of the to-be-arteriovenous fistula surgery patient and the key preoperative detection factor corresponding to the arteriovenous fistula surgery patient type to which the to-be-arteriovenous fistula surgery patient belongs and the influence weight corresponding to the key preoperative detection factor.

[0006] Further, the determining of the plurality of thrombosis risk related diseases, the plurality of thrombosis risk related operations and the plurality of thrombosis risk related drugs based on the medical history information, the treatment information and the postoperative thrombosis monitoring information of the plurality of arteriovenous fistula surgery patients comprises: determining a plurality of to-be-screened diseases, a plurality of to-be-screened operations and a plurality of to-be-screened drugs; for each to-be-screened disease, determining a thrombosis risk influence coefficient of the to-be-screened disease based on the medical history information and the postoperative thrombosis monitoring information of the plurality of arteriovenous fistula surgery patients, and determining whether the to-be-screened disease is a thrombosis risk related disease based on the thrombosis risk related coefficient of the to-be-screened disease; for each to-be-screened operation, determining a thrombosis risk influence coefficient of the to-be-screened operation based on the treatment information and the postoperative thrombosis monitoring information of the plurality of arteriovenous fistula surgery patients, and determining whether the to-be-screened operation is a thrombosis risk related operation based on the thrombosis risk related coefficient of the to-be-screened operation; and for each to-be-screened drug, determining a thrombosis risk influence coefficient of the to-be-screened drug based on the treatment information and the postoperative thrombosis monitoring information of the plurality of arteriovenous fistula surgery patients, and determining whether the to-be-screened drug is a thrombosis risk related drug based on the thrombosis risk related coefficient of the to-be-screened drug.

[0007] Further, based on the medical information of the plurality of arteriovenous fistula surgery patients and the plurality of thrombosis risk related diseases, the plurality of thrombosis risk related surgeries and the plurality of thrombosis risk related drugs, a plurality of patient types are determined, including: determining the thrombosis risk related surgeries and the thrombosis risk related drugs related to each thrombosis risk related disease; determining the thrombosis risk joint influence coefficients between the plurality of thrombosis risk related diseases, the thrombosis risk joint influence coefficients between the plurality of thrombosis risk related surgeries and the thrombosis risk joint influence coefficients between the plurality of risk related drugs based on the medical information of the plurality of arteriovenous fistula surgery patients; and determining the plurality of patient types based on the thrombosis risk joint influence coefficients between the plurality of thrombosis risk related diseases, the thrombosis risk joint influence coefficients between the plurality of thrombosis risk related surgeries and the thrombosis risk joint influence coefficients between the plurality of risk related drugs.

[0008] Further, based on the medical information of the plurality of arteriovenous fistula surgery patients, the thrombosis risk joint influence coefficients between the plurality of thrombosis risk related diseases, the thrombosis risk joint influence coefficients between the plurality of thrombosis risk related surgeries and the thrombosis risk joint influence coefficients between the plurality of risk related drugs are determined, including: determining the disease risk joint influence coefficients between any two thrombosis risk related diseases based on the medical history information and postoperative thrombosis monitoring information of the plurality of arteriovenous fistula surgery patients; determining a plurality of thrombosis risk related disease units based on the disease risk joint influence coefficients between any two thrombosis risk related diseases, wherein the thrombosis risk related disease unit includes two thrombosis risk related diseases; and for each thrombosis risk related disease unit, determining the surgery risk joint influence coefficients of any two thrombosis risk related surgeries and the drug risk joint influence coefficients of any two thrombosis risk related drugs corresponding to the thrombosis risk related disease unit based on the thrombosis risk related surgeries and the thrombosis risk related drugs related to each thrombosis risk related disease and the treatment information and postoperative thrombosis monitoring information of the plurality of arteriovenous fistula surgery patients.

[0009] Further, based on the thrombosis risk joint influence coefficients between the plurality of thrombosis risk related diseases, the thrombosis risk joint influence coefficients between the plurality of thrombosis risk related surgeries and the thrombosis risk joint influence coefficients between the plurality of risk related drugs, the plurality of patient types are determined, including: for each thrombosis risk related disease unit, determining the unit risk joint influence coefficients corresponding to the thrombosis risk related disease unit based on the disease risk joint influence coefficients between the two thrombosis risk related diseases included in the thrombosis risk related disease unit and the surgery risk joint influence coefficients of any two thrombosis risk related surgeries and the drug risk joint influence coefficients of any two thrombosis risk related drugs corresponding to the thrombosis risk related disease unit; grouping the plurality of thrombosis risk related diseases according to the unit risk joint influence coefficients corresponding to each thrombosis risk related disease unit to determine a plurality of thrombosis risk related disease groups; and determining the plurality of patient types according to the plurality of thrombosis risk related disease groups.

[0010] Further, based on the preoperative detection information of the plurality of arteriovenous fistula surgery patients included in the arteriovenous fistula surgery patient type, the key preoperative detection factor corresponding to the arteriovenous fistula surgery patient type and the influence weight corresponding to the key preoperative detection factor are determined, including: based on the thrombosis risk related disease group corresponding to the arteriovenous fistula surgery patient type, a plurality of preoperative detection factors to be screened are determined; based on the preoperative detection information and postoperative thrombosis monitoring information of the plurality of arteriovenous fistula surgery patients included in the arteriovenous fistula surgery patient type, the thrombosis risk influence coefficient of each preoperative detection factor to be screened corresponding to the arteriovenous fistula surgery patient type is determined; based on the thrombosis risk influence coefficient of each preoperative detection factor to be screened corresponding to the arteriovenous fistula surgery patient type, the key preoperative detection factor corresponding to the arteriovenous fistula surgery patient type and the influence weight corresponding to the key preoperative detection factor are determined.

[0011] Further, based on the thrombosis risk influence coefficient of each preoperative detection factor to be screened corresponding to the arteriovenous fistula surgery patient type, the key preoperative detection factor corresponding to the arteriovenous fistula surgery patient type and the influence weight corresponding to the key preoperative detection factor are determined, including: based on the thrombosis risk influence coefficient of each preoperative detection factor to be screened corresponding to the arteriovenous fistula surgery patient type and the thrombosis risk influence threshold, the key preoperative detection factor corresponding to the arteriovenous fistula surgery patient type is determined; based on the thrombosis risk influence coefficient of each key preoperative detection factor corresponding to each arteriovenous fistula surgery patient type, the influence weight corresponding to each key preoperative detection factor is determined.

[0012] Further, based on the preoperative detection information of the arteriovenous fistula surgery patient to be operated and the key preoperative detection factor corresponding to the arteriovenous fistula surgery patient type to which the arteriovenous fistula surgery patient belongs and the influence weight corresponding to the key preoperative detection factor, the preoperative thrombosis risk of the arteriovenous fistula surgery is evaluated, including: for each arteriovenous fistula surgery patient type, based on the key preoperative detection factor corresponding to the arteriovenous fistula surgery patient type and the influence weight corresponding to the key preoperative detection factor, a risk assessment model corresponding to the arteriovenous fistula surgery patient type is established; through the risk assessment model corresponding to the arteriovenous fistula surgery patient type to which the arteriovenous fistula surgery patient to be operated belongs, based on the preoperative detection information of the arteriovenous fistula surgery patient to be operated, the preoperative thrombosis risk of the arteriovenous fistula surgery is evaluated.

[0013] Further, by the risk assessment model corresponding to the type of arteriovenous fistula surgery patient to which the to-be-operated arteriovenous fistula surgery patient belongs, the preoperative thrombosis risk of the arteriovenous fistula surgery is evaluated based on the preoperative detection information of the to-be-operated arteriovenous fistula surgery patient, including: determining the matching value of the type of arteriovenous fistula surgery patient to which the to-be-operated arteriovenous fistula surgery patient belongs based on the medical history information and treatment information of the to-be-operated arteriovenous fistula surgery patient; determining the arteriovenous fistula surgery thrombosis risk value based on the preoperative detection information of the to-be-operated arteriovenous fistula surgery patient through the risk assessment model corresponding to the type of arteriovenous fistula surgery patient to which the to-be-operated arteriovenous fistula surgery patient belongs; and determining the arteriovenous fistula surgery thrombosis comprehensive risk value based on the matching value of each type of arteriovenous fistula surgery patient to which the to-be-operated arteriovenous fistula surgery patient belongs and the arteriovenous fistula surgery thrombosis risk value output by the corresponding risk assessment model through a comprehensive evaluation model.

[0014] The application provides an arteriovenous fistula surgery preoperative thrombosis risk evaluation system, which applies the arteriovenous fistula surgery preoperative thrombosis risk evaluation method, and comprises: an information acquisition module, which is used to acquire medical information of a plurality of arteriovenous fistula surgery patients, wherein the medical information at least includes medical history information, treatment information, preoperative detection information and postoperative thrombosis monitoring information; a correlation analysis module, which is used to determine a plurality of thrombosis risk related diseases, a plurality of thrombosis risk related operations and a plurality of thrombosis risk related drugs based on the medical history information, the treatment information and the postoperative thrombosis monitoring information of the plurality of arteriovenous fistula surgery patients; a type analysis module, which is used to determine a plurality of arteriovenous fistula surgery patient types based on the medical information of the plurality of arteriovenous fistula surgery patients and the plurality of thrombosis risk related diseases, the plurality of thrombosis risk related operations and the plurality of thrombosis risk related drugs; a factor analysis module, which is used to determine, for each arteriovenous fistula surgery patient type, a key preoperative detection factor corresponding to the arteriovenous fistula surgery patient type and an influence weight corresponding to the key preoperative detection factor based on the preoperative detection information and the postoperative thrombosis monitoring information of a plurality of arteriovenous fistula surgery patients included in the arteriovenous fistula surgery patient type; a type determination module, which is used to determine the arteriovenous fistula surgery patient type to which a to-be-operated arteriovenous fistula surgery patient belongs based on the medical history information and the treatment information of the to-be-operated arteriovenous fistula surgery patient; and a risk evaluation module, which is used to evaluate the preoperative thrombosis risk of the arteriovenous fistula surgery based on the preoperative detection information of the to-be-operated arteriovenous fistula surgery patient and the key preoperative detection factor corresponding to the arteriovenous fistula surgery patient type to which the to-be-operated arteriovenous fistula surgery patient belongs and the influence weight corresponding to the key preoperative detection factor.

[0015] Compared with the prior art, the arteriovenous fistula surgery preoperative thrombosis risk evaluation method and system provided by the application has at least the following beneficial effects:

[0016] 1. By analyzing the medical information of multiple patients, different patient types and their specific thrombosis risk factors can be identified. For patients undergoing surgery, a more personalized thrombosis risk assessment can be performed based on their patient type, thereby improving the accuracy of the assessment. By determining key preoperative detection factors and their influence weights, targeted detection of patients before surgery can be performed. If a patient is found to have a high thrombosis risk, intervention measures such as adjusting medication, changing the surgical plan, or strengthening postoperative monitoring can be taken in advance, thereby effectively preventing thrombosis and ensuring the safety and success of the surgery. By preventing thrombosis, surgical complications can be reduced, thereby improving the success rate of surgery and the recovery speed of patients.

[0017] 2. By determining the thrombosis risk influence coefficients of diseases, surgeries, and drugs to be screened, this method uses a scientific and quantitative approach to assess their relationship with thrombosis risk. It is more accurate than traditional experience-based judgment or subjective speculation, and can more truly reflect the influence of diseases, surgeries, and drugs on thrombosis risk. It systematically considers the influence of multiple diseases, surgeries, and drugs on thrombosis risk, rather than focusing on a single factor. This comprehensive assessment approach helps to better understand the thrombosis risk status of patients and provides stronger support for subsequent surgical decision-making and risk management.

[0018] 3. By determining the combined influence coefficients of multiple thrombosis risk-related diseases, surgeries, and drugs, this method can more finely classify patients. This classification method considers the interaction between multiple factors, making the division of patient types more accurate and targeted. It not only considers the influence of a single disease, surgery, or drug on thrombosis risk, but also considers their combined effect. This comprehensive assessment approach can more truly reflect the thrombosis risk status of patients and provide more comprehensive information for surgical decision-making and risk management. By determining patient types and their corresponding key preoperative detection factors and influence weights, more accurate thrombosis risk assessment can be performed.

[0019] 4. By establishing specific risk assessment models for each arteriovenous fistula surgery patient type, personalized assessment of patient thrombosis risk can be achieved. This personalized assessment considers the specific characteristics of patient types and key preoperative detection factors, making the assessment results more accurate and targeted. Using the risk assessment model corresponding to the patient type, combined with the patient's preoperative detection information, the patient's thrombosis risk can be more accurately assessed. This assessment method reduces subjective judgment and experience dependence, improving the objectivity and accuracy of the assessment. By integrating the assessment model, the matching values of multiple patient types to which the patient belongs and the thrombosis risk values output by the corresponding risk assessment models can be considered comprehensively. This comprehensive assessment approach can more comprehensively reflect the thrombosis risk status of patients and provide more comprehensive information for surgical decision-making. BRIEF DESCRIPTION OF DRAWINGS

[0020] The present specification will be further illustrated in the manner of exemplary embodiments, which will be described in detail with reference to the accompanying drawings. These embodiments are not restrictive, and in these embodiments, the same numbers represent the same structures, wherein: Figure 1 is a flowchart of a method for evaluating thrombosis risk before arteriovenous fistula surgery according to some embodiments of the present specification;

[0021] Figure 2 is a module diagram of a system for evaluating thrombosis risk before arteriovenous fistula surgery according to some embodiments of the present specification. DETAILED DESCRIPTION

[0022] In order to more clearly illustrate the technical solutions of the embodiments of the present specification, the drawings needed to be used in the embodiment description will be briefly introduced below. Obviously, the drawings in the following description are only some examples or embodiments of the present specification, and for those skilled in the art, the present specification can also be applied to other similar scenarios without creative labor. Unless it is obvious from the language environment or otherwise stated, the same reference numbers in the drawings represent the same structure or operation.

[0023] Figure 1 is a flowchart of a method for evaluating thrombosis risk before arteriovenous fistula surgery according to some embodiments of the present specification, as shown in Figure 1 , a method for evaluating thrombosis risk before arteriovenous fistula surgery can include the following flow.

[0024] S101, obtaining medical information of a plurality of arteriovenous fistula surgery patients.

[0025] Among them, the medical information at least includes medical history information, treatment information, preoperative detection information and postoperative thrombosis monitoring information. The medical history information can include past medical history, family history. The treatment information can include drug treatment information (such as drug name, drug dosage and cumulative drug duration, etc.) and surgical treatment information (such as surgical method, surgical date, etc.) received by the patient for the past medical history. The preoperative detection information can include biochemical detection, blood routine, vascular ultrasound detection information, etc. The postoperative thrombosis monitoring information can include whether arteriovenous fistula postoperative thrombosis occurs.

[0026] For example only, the medical information of arteriovenous fistula surgery patient A can include:

[0027] 1. Medical history information:

[0028] Past medical history: male, 52 years old, with chronic renal failure for 5 years, has progressed to the uremic stage, and needs long-term hemodialysis treatment. Also has a history of hypertension for 12 years, which is still under control.

[0029] Family history: father died of diabetic nephropathy.

[0030] 2. Treatment information:

[0031] Drug treatment information: long-term use of antihypertensive drugs (such as amlodipine, 1 tablet per day, cumulative drug use for 12 years) and blood sugar control drugs (due to normal blood sugar in recent years, the drug has been discontinued).

[0032] Surgical treatment information: none.

[0033] 3. Preoperative test information:

[0034] Biochemical tests: serum creatinine and urea nitrogen are elevated, consistent with uremic manifestations; blood sugar is normal.

[0035] Blood routine: hemoglobin is slightly low, with mild anemia.

[0036] Vascular ultrasound test information: the diameter of the forearm radial artery and the internal jugular vein is normal, with no thrombus or stenosis, suitable for arteriovenous fistula surgery.

[0037] 4. Postoperative thrombus monitoring information:

[0038] No postoperative thrombosis of the arteriovenous fistula occurred, and the internal fistula tremor and noise were good, with unobstructed blood flow.

[0039] S102, based on the medical history information, treatment information and postoperative thrombus monitoring information of multiple arteriovenous fistula surgery patients, determine multiple thrombosis risk related diseases, multiple thrombosis risk related surgeries and multiple thrombosis risk related drugs.

[0040] Specifically includes:

[0041] Determine multiple diseases to be screened (e.g., diabetes, hypertension, atherosclerosis, etc.), multiple surgeries to be screened (e.g., vascular reconstruction, vascular bypass surgery, etc.), and multiple drugs to be screened (e.g., erythropoietin, anticoagulant drugs, etc.), which can be determined by artificial or big data, for example, to determine multiple diseases to be screened, multiple surgeries to be screened and multiple drugs to be screened;

[0042] For each disease to be screened, based on the medical history information and postoperative thrombus monitoring information of multiple arteriovenous fistula surgery patients, determine the thrombosis risk impact coefficient of the disease to be screened, and determine whether the disease to be screened is a thrombosis risk related disease based on the thrombosis risk related coefficient of the disease to be screened, for example, the disease to be screened with a thrombosis risk impact coefficient greater than a first thrombosis risk impact coefficient threshold is a thrombosis risk related disease.

[0043] For each surgery to be screened, based on the treatment information and postoperative thrombosis monitoring information of a plurality of arteriovenous fistula surgery patients, a thrombosis risk influence coefficient of the surgery to be screened is determined, and whether the surgery to be screened is a thrombosis risk related surgery is determined based on the thrombosis risk related coefficient of the surgery to be screened, for example, the surgery to be screened with a thrombosis risk influence coefficient greater than a second thrombosis risk influence coefficient threshold can be a thrombosis risk related surgery.

[0044] For each drug to be screened, based on the treatment information and postoperative thrombosis monitoring information of a plurality of arteriovenous fistula surgery patients, a thrombosis risk influence coefficient of the drug to be screened is determined, and whether the drug to be screened is a thrombosis risk related drug is determined based on the thrombosis risk related coefficient of the drug to be screened, for example, the drug to be screened with a thrombosis risk influence coefficient greater than a third thrombosis risk influence coefficient threshold can be a thrombosis risk related drug.

[0045] For example, the thrombosis risk influence coefficient of the disease to be screened can be calculated according to the following formula: Wherein, INF (i,1) is the thrombosis risk influence coefficient of the i-th disease to be screened, mark (n,i) is the mark value of the i-th disease to be screened corresponding to the n-th arteriovenous fistula surgery patient, when the medical history information of the n-th arteriovenous fistula surgery patient has the i-th disease to be screened, mark (n,i) = 1, otherwise 0, mark (n,thrombus) is the mark value of the n-th arteriovenous fistula surgery patient corresponding to the thrombosis after arteriovenous fistula surgery, when the postoperative thrombosis monitoring information of the n-th arteriovenous fistula surgery patient has thrombosis, mark (n,thrombus) = 1, otherwise 0, and N is the total number of arteriovenous fistula surgery patients.

[0046] The calculation method of the thrombosis risk influence coefficient of the surgery to be screened and the thrombosis risk influence coefficient of the drug to be screened is consistent with the calculation method of the thrombosis risk influence coefficient of the disease to be screened, which will not be described here.

[0047] S103, based on the medical information of a plurality of arteriovenous fistula surgery patients and a plurality of thrombosis risk related diseases, a plurality of thrombosis risk related surgeries and a plurality of thrombosis risk related drugs, a plurality of arteriovenous fistula surgery patient types are determined.

[0048] Specifically, it includes:

[0049] determine the thrombosis risk related operation and the thrombosis risk related drug related to each thrombosis risk related disease, specifically, the thrombosis risk related operation related to the thrombosis risk related disease can be a thrombosis risk related operation for treating the thrombosis risk related disease, and the thrombosis risk related drug related to the thrombosis risk related disease can be a thrombosis risk related drug for treating the thrombosis risk related disease, which can be determined by manual or big data;

[0050] determine the thrombosis risk combined influence coefficient between the plurality of thrombosis risk related diseases, the thrombosis risk combined influence coefficient between the plurality of thrombosis risk related operations, and the thrombosis risk combined influence coefficient between the plurality of risk related drugs based on the medical information of the plurality of arteriovenous fistula operation patients;

[0051] determine the plurality of patient types based on the thrombosis risk combined influence coefficient between the plurality of thrombosis risk related diseases, the thrombosis risk combined influence coefficient between the plurality of thrombosis risk related operations, and the thrombosis risk combined influence coefficient between the plurality of risk related drugs.

[0052] In some embodiments, the thrombosis risk combined influence coefficient between the plurality of thrombosis risk related diseases, the thrombosis risk combined influence coefficient between the plurality of thrombosis risk related operations, and the thrombosis risk combined influence coefficient between the plurality of risk related drugs are determined based on the medical information of the plurality of arteriovenous fistula operation patients, including:

[0053] determine the disease risk combined influence coefficient between any two thrombosis risk related diseases based on the medical history information and postoperative thrombosis monitoring information of the plurality of arteriovenous fistula operation patients;

[0054] determine a plurality of thrombosis risk related disease units based on the disease risk combined influence coefficient between any two thrombosis risk related diseases, wherein the thrombosis risk related disease unit includes two thrombosis risk related diseases;

[0055] For each thrombosis risk related disease unit, based on the thrombosis risk related surgeries and the thrombosis risk related drugs related to each thrombosis risk related disease, and the treatment information and postoperative thrombosis monitoring information of the arteriovenous fistula surgery patients, the surgical risk joint influence coefficient of any two thrombosis risk related surgeries and the drug risk joint influence coefficient of any two thrombosis risk related drugs corresponding to the thrombosis risk related disease unit are determined. For example, the thrombosis risk related disease unit includes thrombosis risk related disease A and thrombosis risk related disease B, the thrombosis risk related surgeries related to the thrombosis risk related disease A include thrombosis risk related surgery C1 and thrombosis risk related surgery C2, and the thrombosis risk related surgeries related to the thrombosis risk related disease B include thrombosis risk related surgery C3. The surgical risk joint influence coefficient of the thrombosis risk related surgery C1 and the thrombosis risk related surgery C3 and the surgical risk joint influence coefficient of the thrombosis risk related surgery C2 and the thrombosis risk related surgery C3 need to be calculated.

[0056] For example, based on the postoperative thrombosis monitoring information of the arteriovenous fistula surgery patients, the arteriovenous fistula surgery patients with thrombosis are determined, and based on the medical history information of the arteriovenous fistula surgery patients with thrombosis, the disease risk joint influence coefficient between any two thrombosis risk related diseases is determined.

[0057] The disease risk joint influence coefficient between two thrombosis risk related diseases can be calculated according to the following formula: Wherein, INF (i,j,1) is the disease risk joint influence coefficient between the i-th thrombosis risk related disease and the j-th thrombosis risk related disease, mark (m,i) is the mark value of the i-th disease to be screened corresponding to the m-th arteriovenous fistula surgery patient with thrombosis, when the i-th disease to be screened exists in the medical history information of the m-th arteriovenous fistula surgery patient with thrombosis, mark (m,i) = 1, otherwise 0, mark (m，j) is the mark value of the j-th disease to be screened corresponding to the m-th arteriovenous fistula surgery patient with thrombosis, when the j-th disease to be screened exists in the medical history information of the m-th arteriovenous fistula surgery patient with thrombosis, mark (m，j) = 1, otherwise 0, and M is the total number of arteriovenous fistula surgery patients with thrombosis.

[0058] The calculation method of the surgical risk joint influence coefficient of any two thrombosis risk related surgeries and the drug risk joint influence coefficient of any two thrombosis risk related drugs is consistent with the calculation method of the disease risk joint influence coefficient between two thrombosis risk related diseases, which will not be repeated here.

[0059] In some embodiments, based on the combined thrombosis risk influence coefficients between multiple thrombosis risk related diseases, the combined thrombosis risk influence coefficients between multiple thrombosis risk related surgeries, and the combined thrombosis risk influence coefficients between multiple risk related drugs, a plurality of patient types are determined, including:

[0060] For each thrombosis risk related disease unit, based on the combined disease risk influence coefficients between two thrombosis risk related diseases included in the thrombosis risk related disease unit, and the combined surgery risk influence coefficients of any two thrombosis risk related surgeries corresponding to the thrombosis risk related disease unit and the combined drug risk influence coefficients of any two thrombosis risk related drugs, a unit risk combined influence coefficient corresponding to the thrombosis risk related disease unit is determined.

[0061] According to the unit risk combined influence coefficient corresponding to each thrombosis risk related disease unit, the plurality of thrombosis risk related diseases are grouped to determine a plurality of thrombosis risk related disease groups. For example, a clustering algorithm can be used to group the plurality of thrombosis risk related diseases according to the unit risk combined influence coefficient corresponding to each thrombosis risk related disease unit to determine a plurality of thrombosis risk related disease groups.

[0062] According to the plurality of thrombosis risk related disease groups, a plurality of patient types are determined.

[0063] The unit risk combined influence coefficient corresponding to the thrombosis risk related disease unit can be calculated according to the following formula: wherein INF (k，unit) is the unit risk combined influence coefficient corresponding to the kth thrombosis risk related disease unit, INF (i，j，1) is the combined disease risk influence coefficient of the two thrombosis risk related diseases included in the kth thrombosis risk related disease unit, INF (e，f，2) is the combined surgery risk influence coefficient of the e th thrombosis risk related surgery related to one thrombosis risk related disease and the f th thrombosis risk related surgery related to another thrombosis risk related disease included in the kth thrombosis risk related disease unit, and INF (g,h,3)Let E be the combined drug risk coefficient of the g-th thrombosis-related drug associated with one thrombosis-related disease and the h-th thrombosis-related drug associated with another thrombosis-related disease in the k-th thrombosis-related disease unit; let E be the total number of thrombosis-related surgeries associated with one thrombosis-related disease in the k-th thrombosis-related disease unit; let F be the total number of thrombosis-related surgeries associated with another thrombosis-related disease in the k-th thrombosis-related disease unit; let G be the total number of thrombosis-related drugs associated with one thrombosis-related disease in the k-th thrombosis-related disease unit; let H be the total number of thrombosis-related drugs associated with another thrombosis-related disease in the k-th thrombosis-related disease unit; and let w be the total number of thrombosis-related drugs associated with one thrombosis-related disease in the k-th thrombosis-related disease unit. 11 w 12 and w 13 For weights, w 11 w 12 and w 13 Greater than 0, w 11 +w 12 +w 13 =1.

[0064] Patient types can include patient types corresponding to each thrombosis risk-related disease group and patient types that do not correspond to any of the thrombosis risk-related disease groups. For example, multiple thrombosis risk-related disease groups include thrombosis risk-related disease group A (atherosclerosis, diabetic vascular disease, systemic lupus erythematosus), thrombosis risk-related disease group B (anticoagulant deficiency, hyperlipidemia), and thrombosis risk-related disease group C (congestive heart failure, valvular heart disease). Then, multiple patient types can include patient type A corresponding to thrombosis risk-related disease group A, patient type B corresponding to thrombosis risk-related disease group B, patient type C corresponding to thrombosis risk-related disease group C, and patient type D. When a patient's medical history includes atherosclerosis, diabetic vascular disease, systemic lupus erythematosus, etc. If a patient has at least one of the following conditions: systemic lupus erythematosus, then the patient's patient type includes patient type A. If a patient's medical history includes at least one of anticoagulant deficiency or hyperlipidemia, then the patient's patient type includes patient type B. If a patient's medical history includes at least one of congestive heart failure or valvular disease, then the patient's patient type includes patient type C. If a patient's medical history does not include atherosclerosis, diabetic vascular disease, systemic lupus erythematosus, anticoagulant deficiency, hyperlipidemia, congestive heart failure, or valvular disease, then the patient's patient type is patient type D.

[0065] It can be understood that by comprehensively considering the combined influence coefficients among diseases, operations and drugs, the method can more finely stratify the risk of thrombosis related diseases. This stratification not only considers the risk contribution of a single factor, but also considers the interaction between multiple factors, making the risk stratification more accurate and detailed.

[0066] S104, for each arteriovenous fistula surgery patient type, based on the preoperative detection information and postoperative thrombosis monitoring information of the multiple arteriovenous fistula surgery patients included in the arteriovenous fistula surgery patient type, determine the key preoperative detection factor corresponding to the arteriovenous fistula surgery patient type and the influence weight corresponding to the key preoperative detection factor.

[0067] Specifically includes:

[0068] Based on the thrombosis risk related disease group corresponding to the arteriovenous fistula surgery patient type, determine the multiple preoperative detection factors (for example, prothrombin time, activated partial thromboplastin time, thrombin time, fibrinogen, whole blood viscosity, hematocrit, von willebrand factor, soluble thrombomodulin, cardiac ejection fraction, etc.) corresponding to the arteriovenous fistula surgery patient type. The multiple preoperative detection factors corresponding to the arteriovenous fistula surgery patient type can be determined manually or by big data;

[0069] Based on the preoperative detection information and postoperative thrombosis monitoring information of the multiple arteriovenous fistula surgery patients included in the arteriovenous fistula surgery patient type, determine the thrombosis risk influence coefficient of each preoperative detection factor corresponding to the arteriovenous fistula surgery patient type; based on the thrombosis risk influence coefficient of each preoperative detection factor corresponding to the arteriovenous fistula surgery patient type, determine the key preoperative detection factor corresponding to the arteriovenous fistula surgery patient type and the influence weight corresponding to the key preoperative detection factor.

[0070] As an example, the multiple preoperative detection factors corresponding to different arteriovenous fistula surgery patient types can be as shown in Table 1.

[0071] Table 1: Multiple preoperative detection factors corresponding to different arteriovenous fistula surgery patient types

[0072] The thrombosis risk influence coefficient of the preoperative detection factor to be screened can be calculated according to the following formula: Where, INF (r,factor) is the thrombosis risk influence coefficient of the rth preoperative detection factor to be screened corresponding to the arteriovenous fistula surgery patient type, mark (r，t)mark (r,t) = 1, otherwise 0, mark (t,thrombus) mark (t,thrombus) = 1, otherwise 0, T is the total number of the internal arteriovenous fistula surgery patients included in the internal arteriovenous fistula surgery patient type.

[0073] In some embodiments, based on the thrombosis risk influence coefficient of each preoperative detection factor to be screened corresponding to the internal arteriovenous fistula surgery patient type, the key preoperative detection factor corresponding to the internal arteriovenous fistula surgery patient type and the influence weight corresponding to the key preoperative detection factor are determined, comprising:

[0074] Based on the thrombosis risk influence coefficient of each preoperative detection factor to be screened corresponding to the internal arteriovenous fistula surgery patient type and the thrombosis risk influence threshold value, the key preoperative detection factor corresponding to the internal arteriovenous fistula surgery patient type is determined, for example, the preoperative detection factor to be screened with a thrombosis risk influence coefficient greater than the thrombosis risk influence threshold value is taken as the key preoperative detection factor;

[0075] Based on the thrombosis risk influence coefficient of each key preoperative detection factor corresponding to each internal arteriovenous fistula surgery patient type, the influence weight corresponding to each key preoperative detection factor is determined.

[0076] The influence weight corresponding to the key preoperative detection factor can be calculated according to the following formula: wherein, is the influence weight corresponding to the i-th key preoperative detection factor, INF (i,factor) is the thrombosis risk influence coefficient of the i-th key preoperative detection factor, INF (d,factor) is the thrombosis risk influence coefficient of the d-th key preoperative detection factor, and D is the total number of key preoperative detection factors.

[0077] S105, based on the medical history information and treatment information of the internal arteriovenous fistula surgery patient to be screened, the internal arteriovenous fistula surgery patient type to which the internal arteriovenous fistula surgery patient to be screened belongs is determined.

[0078] Specifically, when the medical history information of the internal arteriovenous fistula surgery patient to be screened has a disease corresponding to a certain internal arteriovenous fistula surgery patient type, the internal arteriovenous fistula surgery patient to be screened belongs to the internal arteriovenous fistula surgery patient type.

[0079] S106, based on the arteriovenous fistula surgery patient type to which the arteriovenous fistula surgery patient belongs, obtaining the preoperative detection information of the arteriovenous fistula surgery patient.

[0080] Specifically, the key preoperative detection factors corresponding to the arteriovenous fistula surgery patient type to which the arteriovenous fistula surgery patient belongs are determined, the preoperative detection items are determined, and the preoperative detection information of the arteriovenous fistula surgery patient is determined, wherein the preoperative detection information of the arteriovenous fistula surgery patient can include the value of each key preoperative detection factor corresponding to the arteriovenous fistula surgery patient type.

[0081] S107, based on the preoperative detection information of the arteriovenous fistula surgery patient and the key preoperative detection factors corresponding to the arteriovenous fistula surgery patient type to which the arteriovenous fistula surgery patient belongs and the influence weight corresponding to the key preoperative detection factor, the thrombosis risk assessment before arteriovenous fistula surgery is performed.

[0082] Specifically, it includes:

[0083] For each arteriovenous fistula surgery patient type, based on the key preoperative detection factors corresponding to the arteriovenous fistula surgery patient type and the influence weight corresponding to the key preoperative detection factor, a risk assessment model corresponding to the arteriovenous fistula surgery patient type is established, wherein the risk assessment model can be a convolutional neural network model.

[0084] Through the risk assessment model corresponding to the arteriovenous fistula surgery patient type to which the arteriovenous fistula surgery patient belongs, the preoperative detection information of the arteriovenous fistula surgery patient is used to perform the thrombosis risk assessment before arteriovenous fistula surgery.

[0085] In some embodiments, the thrombosis risk assessment before arteriovenous fistula surgery is performed by the risk assessment model corresponding to the arteriovenous fistula surgery patient type to which the arteriovenous fistula surgery patient belongs, based on the preoperative detection information of the arteriovenous fistula surgery patient, including:

[0086] Based on the medical history information and treatment information of the arteriovenous fistula surgery patient, a matching value of the arteriovenous fistula surgery patient type to which the arteriovenous fistula surgery patient belongs is determined, for example, a matching value determination model can be used to determine the matching value of the arteriovenous fistula surgery patient type to which the arteriovenous fistula surgery patient belongs based on the medical history information and treatment information of the arteriovenous fistula surgery patient, wherein the matching value determination model can be a convolutional neural network model.

[0087] Through the risk assessment model corresponding to the arteriovenous fistula surgery patient type to which the arteriovenous fistula surgery patient belongs, the preoperative detection information of the arteriovenous fistula surgery patient is used to determine the thrombosis risk value of arteriovenous fistula surgery;

[0088] The comprehensive evaluation model is a convolutional neural network model.

[0089] Figure 2 is a schematic diagram of a module of an evaluation system for preoperative thrombosis risk of arteriovenous fistula surgery according to some embodiments of the present specification, as Figure 2 An evaluation system for preoperative thrombosis risk of arteriovenous fistula surgery can include an information acquisition module, a correlation analysis module, a type analysis module, a factor analysis module, a type determination module, and a risk assessment module.

[0090] The information acquisition module is configured to acquire medical information of a plurality of arteriovenous fistula surgery patients, wherein the medical information at least includes medical history information, treatment information, preoperative detection information, and postoperative thrombosis monitoring information.

[0091] The correlation analysis module is configured to determine a plurality of thrombosis risk related diseases, a plurality of thrombosis risk related surgeries, and a plurality of thrombosis risk related drugs based on the medical history information, the treatment information, and the postoperative thrombosis monitoring information of the plurality of arteriovenous fistula surgery patients.

[0092] The type analysis module is configured to determine a plurality of arteriovenous fistula surgery patient types based on the medical information of the plurality of arteriovenous fistula surgery patients and the plurality of thrombosis risk related diseases, the plurality of thrombosis risk related surgeries, and the plurality of thrombosis risk related drugs.

[0093] The factor analysis module is configured to determine, for each arteriovenous fistula surgery patient type, a key preoperative detection factor corresponding to the arteriovenous fistula surgery patient type and an influence weight corresponding to the key preoperative detection factor based on the preoperative detection information and the postoperative thrombosis monitoring information of a plurality of arteriovenous fistula surgery patients included in the arteriovenous fistula surgery patient type.

[0094] The type determination module is configured to determine an arteriovenous fistula surgery patient type to which a to-be-operated arteriovenous fistula surgery patient belongs based on the medical history information and the treatment information of the to-be-operated arteriovenous fistula surgery patient.

[0095] The information acquisition module is further configured to acquire preoperative detection information of the to-be-operated arteriovenous fistula surgery patient based on the arteriovenous fistula surgery patient type to which the to-be-operated arteriovenous fistula surgery patient belongs.

[0096] The risk assessment module is configured to perform preoperative thrombosis risk assessment of arteriovenous fistula surgery based on the preoperative detection information of the to-be-operated arteriovenous fistula surgery patient and the key preoperative detection factor corresponding to the arteriovenous fistula surgery patient type to which the to-be-operated arteriovenous fistula surgery patient belongs and the influence weight corresponding to the key preoperative detection factor.

[0097] An assessment system for thrombosis risk before an arteriovenous fistula surgery can be used to perform an assessment method for thrombosis risk before an arteriovenous fistula surgery, not described here again.

[0098] Finally, it should be understood that the embodiments described herein are only given by way of example and that other modifications can be made by those skilled in the art without departing from the scope of the disclosure. Thus, the scope of the disclosure is not intended to be limited to the embodiments described herein but is to be accorded the full scope inherent to embodiments defined by the claims attached hereto.

Claims

1. A method for assessing the risk of thrombosis before arteriovenous fistula surgery, characterized in that, include: Obtain medical information from multiple patients undergoing arteriovenous fistula surgery, wherein the medical information includes at least medical history, treatment information, preoperative testing information, and postoperative thrombosis monitoring information; Based on the medical history, treatment information, and postoperative thrombosis monitoring information of multiple arteriovenous fistula surgeries, various thrombosis risk-related diseases, various thrombosis risk-related surgeries, and various thrombosis risk-related drugs were identified. Based on the medical information of multiple arteriovenous fistula surgery patients, as well as multiple thrombosis-related diseases, multiple thrombosis-related surgeries, and multiple thrombosis-related drugs, we identified multiple types of arteriovenous fistula surgery patients. For each type of arteriovenous fistula surgery patient, based on the preoperative testing information and postoperative thrombosis monitoring information of multiple arteriovenous fistula surgery patients included in the arteriovenous fistula surgery patient type, the key preoperative testing factors corresponding to the arteriovenous fistula surgery patient type and the influence weights of the key preoperative testing factors are determined. Based on the medical history and treatment information of patients awaiting arteriovenous fistula surgery, the type of arteriovenous fistula surgery patient to which the patients awaiting arteriovenous fistula surgery belong is determined. Based on the type of arteriovenous fistula (AVF) patient to which the patient to undergo AVF surgery belongs, obtain the preoperative testing information of the patient to undergo AVF surgery. Based on the preoperative testing information of patients undergoing arteriovenous fistula surgery, the key preoperative testing factors corresponding to the patient type of arteriovenous fistula surgery, and the influence weights of the key preoperative testing factors, a thrombosis risk assessment is performed before arteriovenous fistula surgery. Based on the medical history, treatment information, and postoperative thrombosis monitoring information of multiple patients who underwent arteriovenous fistula surgery, several thrombosis-related diseases, surgeries, and medications were identified, including: Identify multiple diseases, surgeries, and drugs to be screened; For each disease to be screened, the thrombosis risk impact coefficient of the disease to be screened is determined based on the medical history information and postoperative thrombosis monitoring information of the multiple arteriovenous fistula surgery patients, and the thrombosis risk correlation coefficient of the disease to be screened is used to determine whether the disease to be screened is a thrombosis risk-related disease. For each type of surgery to be screened, based on the treatment information and postoperative thrombosis monitoring information of the multiple arteriovenous fistula surgery patients, the thrombosis risk impact coefficient of the surgery to be screened is determined, and based on the thrombosis risk correlation coefficient of the surgery to be screened, it is determined whether the surgery to be screened is a thrombosis risk-related surgery. For each drug to be screened, based on the treatment information and postoperative thrombosis monitoring information of the multiple arteriovenous fistula surgery patients, the thrombosis risk impact coefficient of the drug to be screened is determined, and based on the thrombosis risk correlation coefficient of the drug to be screened, it is determined whether the drug to be screened is a thrombosis risk-related drug. Based on medical information from multiple arteriovenous fistula surgeries, various thrombosis-related diseases, surgeries, and medications, several patient types were identified, including: Identify the thrombosis-related surgeries and medications associated with each thrombosis-related disease; Based on the medical information of multiple arteriovenous fistula patients, we determined the joint influence coefficient of thrombosis risk among various thrombosis risk-related diseases, the joint influence coefficient of thrombosis risk among various thrombosis risk-related surgeries, and the joint influence coefficient of thrombosis risk among various risk-related drugs. Based on the combined influence coefficients of thrombosis risk among various thrombosis-related diseases, various thrombosis-related surgeries, and various thrombosis-related medications, multiple patient types were identified.

2. The method for assessing the risk of thrombosis before arteriovenous fistula surgery according to claim 1, characterized in that, Based on medical information from multiple arteriovenous fistula surgeries, the joint influence coefficients of thrombosis risk among various thrombosis-related diseases, various thrombosis-related surgeries, and various risk-related medications were determined, including: Based on the medical history and postoperative thrombosis monitoring information of multiple arteriovenous fistula surgery patients, the joint risk coefficient between any two thrombosis-related diseases was determined. Based on the joint risk coefficient between any two thrombosis-related diseases, multiple thrombosis-related disease units are identified, wherein each thrombosis-related disease unit includes two thrombosis-related diseases. For each thrombosis-related disease unit, based on the thrombosis-related surgeries and medications associated with each thrombosis-related disease, as well as the treatment information and postoperative thrombosis monitoring information of multiple arteriovenous fistula surgeries, the combined surgical risk coefficient of any two thrombosis-related surgeries and the combined drug risk coefficient of any two thrombosis-related medications corresponding to the thrombosis-related disease unit are determined.

3. The method for assessing the risk of thrombosis before arteriovenous fistula surgery according to claim 2, characterized in that, Based on the combined thrombosis risk coefficients among various thrombosis-related diseases, various thrombosis-related surgeries, and various risk-related medications, multiple patient types were identified, including: For each thrombosis-related disease unit, the unit risk joint influence coefficient is determined based on the joint influence coefficient of disease risk between the two thrombosis-related diseases included in the thrombosis-related disease unit, the joint influence coefficient of surgical risk of any two thrombosis-related surgeries and the joint influence coefficient of drug risk of any two thrombosis-related drugs corresponding to the thrombosis-related disease unit. Based on the joint risk factor coefficient of each thrombosis-related disease unit, multiple thrombosis-related diseases are grouped to determine multiple thrombosis-related disease groups; Multiple patient types were identified based on various thrombosis risk-related disease groups.

4. The method for assessing the risk of thrombosis before arteriovenous fistula surgery according to claim 2, characterized in that, Based on the preoperative testing information of multiple arteriovenous fistula (AVF) surgery patients included in the aforementioned AVF surgery patient types, key preoperative testing factors corresponding to each AVF surgery patient type and their corresponding influence weights are determined, including: Based on the thrombosis risk-related disease groups corresponding to the patient types of arteriovenous fistula surgery, multiple preoperative detection factors to be screened were identified for the patient types of arteriovenous fistula surgery. Based on the preoperative testing information and postoperative thrombosis monitoring information of multiple arteriovenous fistula surgery patients, including the patient types of arteriovenous fistula surgery, the thrombosis risk impact coefficient of each preoperative testing factor to be screened for the corresponding patient type of arteriovenous fistula surgery was determined. Based on the thrombosis risk impact coefficient of each preoperative detection factor to be screened for arteriovenous fistula surgery patient type, the key preoperative detection factors and their corresponding impact weights for the key preoperative detection factors are determined.

5. The method for assessing the risk of thrombosis before arteriovenous fistula surgery according to claim 4, characterized in that, Based on the thrombosis risk impact coefficient of each preoperative screening factor corresponding to the patient type of arteriovenous fistula surgery, the key preoperative screening factors and their corresponding impact weights for the patient type of arteriovenous fistula surgery are determined, including: Based on the thrombosis risk impact coefficient and thrombosis risk impact threshold of each preoperative detection factor to be screened for arteriovenous fistula surgery patient type, the key preoperative detection factors corresponding to the arteriovenous fistula surgery patient type are determined. Based on the thrombosis risk impact coefficient of key preoperative detection factors corresponding to each type of arteriovenous fistula surgery patient, the impact weight of each key preoperative detection factor is determined.

6. The method for assessing the risk of thrombosis before arteriovenous fistula surgery according to claim 1, characterized in that, Based on the preoperative testing information of patients undergoing arteriovenous fistula (AVF) surgery, the key preoperative testing factors corresponding to the patient type of AVF surgery, and the influence weights of the key preoperative testing factors, a preoperative thrombotic risk assessment is performed for AVF surgery, including: For each type of arteriovenous fistula surgery patient, a risk assessment model is established based on the key preoperative detection factors and their corresponding influence weights. Using a risk assessment model corresponding to the type of arteriovenous fistula (AVF) patient to which the patient to undergo AVF surgery belongs, and based on the preoperative test information of the patient to be AVF surgery, the risk of thrombosis before AVF surgery is assessed.

7. The method for assessing the risk of thrombosis before arteriovenous fistula surgery according to claim 6, characterized in that, Using a risk assessment model corresponding to the patient type of arteriovenous fistula (AVF) surgery, and based on the preoperative testing information of patients undergoing AVF surgery, a preoperative thrombotic risk assessment for AVF surgery is performed, including: Based on the medical history and treatment information of patients awaiting arteriovenous fistula surgery, the matching value of the arteriovenous fistula surgery patient type to which the patients awaiting arteriovenous fistula surgery belong is determined; The risk of thrombosis during arteriovenous fistula surgery is determined by using a risk assessment model corresponding to the type of arteriovenous fistula surgery patient to which the patient belongs, based on the preoperative test information of the patient. The comprehensive risk value of arteriovenous fistula surgery (AVF) is determined by using a comprehensive evaluation model based on the matching value of each AVF patient type to which the patient to undergo AVF surgery belongs and the corresponding risk assessment model output AVF surgery thrombosis risk value.

8. A system for assessing the risk of thrombosis before arteriovenous fistula surgery, characterized in that, A method for assessing the risk of thrombosis before arteriovenous fistula surgery according to any one of claims 1-7, comprising: The information acquisition module is used to acquire medical information of multiple arteriovenous fistula surgery patients, wherein the medical information includes at least medical history information, treatment information, preoperative test information and postoperative thrombosis monitoring information; The correlation analysis module is used to identify various thrombosis-related diseases, thrombosis-related surgeries, and thrombosis-related drugs based on the medical history, treatment information, and postoperative thrombosis monitoring information of multiple arteriovenous fistula surgery patients. The type analysis module is used to determine the type of multiple arteriovenous fistula surgery patients based on their medical information, multiple thrombosis-related diseases, multiple thrombosis-related surgeries, and multiple thrombosis-related medications. The factor analysis module is used to determine the key preoperative detection factors and their corresponding influence weights for each type of arteriovenous fistula surgery patient, based on the preoperative detection information and postoperative thrombosis monitoring information of multiple arteriovenous fistula surgery patients included in the arteriovenous fistula surgery patient type. The type determination module is used to determine the type of arteriovenous fistula surgery patient to which the patient belongs based on the patient's medical history and treatment information. The information acquisition module is also used to acquire preoperative test information of patients undergoing arteriovenous fistula surgery based on the type of arteriovenous fistula surgery patients to which the patients undergoing arteriovenous fistula surgery belong. The risk assessment module is used to assess the risk of thrombosis before arteriovenous fistula surgery based on the preoperative test information of patients undergoing arteriovenous fistula surgery, the key preoperative test factors corresponding to the patient type of arteriovenous fistula surgery, and the influence weights of the key preoperative test factors.

Images